Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276965

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276965

Global Bladder Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 253 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 4800
PDF (Enterprise License) - Printable/Downloadable
USD 7000

Add to Cart

Description

Table of Contents

List of Tables

The global bladder cancer diagnostics market is projected to register a substantial CAGR of 8.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Bladder Cancer Diagnostics Market, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, and Mexico, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, the Philippines, and the Rest of Asia-Pacific, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Turkey, Belgium, and the rest of Europe, South Africa, Saudi Arabia, UAE, Egypt, Israel, and the rest of the Middle East and Africa, Brazil, Argentina, and the rest of South America) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global bladder cancer diagnostics market are:

Rising incidence of bladder cancer globally

Rising awareness for the early diagnosis of bladder cancer

Market Players:

Some of the key market players in the global bladder cancer diagnostics market are listed below:

F. Hoffmann-La Roche Ltd

Merck KGaA

Thermo Fisher Scientific Inc.

Koninklijke Philips N.V.

Bio-Rad Laboratories, Inc.

Agilent Technologies, Inc.

FUJIFILM Corporation

CANON MEDICAL SYSTEMS CORPORATION

Siemens Healthcare GmbH

BD

Illumina

Neusoft Corporation

Abbott

General Electric Company

Hologic

QIAGEN

Cepheid.

Ambu A/S

Time Medical Holding.

MinFound Medical Systems Co., Ltd.

Show more

TABLE OF CONTENTS

1 INTRODUCTION 27

  • 1.1 OBJECTIVES OF THE STUDY 27
  • 1.2 MARKET DEFINITION 27
  • 1.3 OVERVIEW OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET 27
  • 1.4 CURRENCY AND PRICING 28
  • 1.5 LIMITATIONS 29
  • 1.6 MARKETS COVERED 29

2 MARKET SEGMENTATION 31

  • 2.1 MARKETS COVERED 31
  • 2.2 GEOGRAPHICAL SCOPE 32
  • 2.3 YEARS CONSIDERED FOR THE STUDY 33
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
  • 2.6 MULTIVARIATE MODELLING 38
  • 2.7 TEST TYPE SEGMENT LIFELINE CURVE 38
  • 2.8 MARKET END USER COVERAGE GRID 39
  • 2.9 DBMR MARKET POSITION GRID 40
  • 2.10 VENDOR SHARE ANALYSIS 41
  • 2.11 SECONDARY SOURCES 42
  • 2.12 ASSUMPTIONS 42

3 EXECUTIVE SUMMARY 43

4 PREMIUM INSIGHTS 45

  • 4.1 PESTLE ANALYSIS 48
  • 4.2 PORTER'S FIVE FORCES MODEL 49

5 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 50

6 REGULATORY FRAMEWORK 52

  • 6.1 REGULATORY SCENARIO IN THE U.S 52
  • 6.2 REGULATORY SCENARIO IN JAPAN 52
  • 6.3 REGULATORY SCENARIO IN CHINA 53

7 MARKET OVERVIEW 54

  • 7.1 DRIVERS 56
    • 7.1.1 RISING INCIDENCE OF BLADDER CANCER GLOBALLY 56
    • 7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 56
    • 7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 57
    • 7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 57
  • 7.2 RESTRAINTS 58
    • 7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 58
    • 7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 58
    • 7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 58
  • 7.3 OPPORTUNITIES 59
    • 7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 59
    • 7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 59
    • 7.3.3 INCREASE IN THE GERIATRIC POPULATION 60
  • 7.4 CHALLENGES 60
    • 7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 60
    • 7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 61

8 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 62

  • 8.1 OVERVIEW 63
  • 8.2 CYSTOSCOPY 66
  • 8.3 URINE LAB TEST 66
    • 8.3.1 URINE CYTOLOGY 68
    • 8.3.2 URINALYSIS 68
    • 8.3.3 URINE TUMOR MARKER TEST 68
    • 8.3.4 URINE CULTURE 68
    • 8.3.5 OTHERS 68
  • 8.4 BIOPSY 68
  • 8.5 IMAGING TEST 69
    • 8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 70
    • 8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 70
    • 8.5.3 ULTRASOUND 70
    • 8.5.4 INTRAVENOUS PYELOGRAM (IVP) 71
  • 8.6 OTHERS 71

9 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 72

  • 9.1 OVERVIEW 73
  • 9.2 STAGE IV 76
  • 9.3 STAGE III 76
  • 9.4 STAGE II 77
  • 9.5 STAGE I 78

10 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 80

  • 10.1 OVERVIEW 81
  • 10.2 TRANSITIONAL CELL BLADDER CANCER 84
  • 10.3 SQUAMOUS CELL BLADDER CANCER 85
  • 10.4 OTHER CANCER TYPES 86

11 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 87

  • 11.1 OVERVIEW 88
  • 11.2 HOSPITAL 91
  • 11.3 DIAGNOSTIC IMAGING CENTERS 91
  • 11.4 CANCER RESEARCH INSTITUTES 92
  • 11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 93
  • 11.6 ASSOCIATED LABS 94

12 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 95

  • 12.1 OVERVIEW 96
  • 12.2 DIRECT TENDER 99
  • 12.3 RETAIL SALES 99

13 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 101

  • 13.1 OVERVIEW 102
  • 13.2 NORTH AMERICA 107
    • 13.2.1 U.S. 114
    • 13.2.2 CANADA 116
    • 13.2.3 MEXICO 118
  • 13.3 EUROPE 120
    • 13.3.1 GERMANY 127
    • 13.3.2 FRANCE 129
    • 13.3.3 U.K. 131
    • 13.3.4 ITALY 133
    • 13.3.5 SPAIN 135
    • 13.3.6 RUSSIA 137
    • 13.3.7 TURKEY 139
    • 13.3.8 NETHERLANDS 141
    • 13.3.9 BELGIUM 143
    • 13.3.10 SWITZERLAND 145
    • 13.3.11 REST OF EUROPE 147
  • 13.4 ASIA-PACIFIC 148
    • 13.4.1 CHINA 155
    • 13.4.2 INDIA 157
    • 13.4.3 JAPAN 159
    • 13.4.4 SOUTH KOREA 161
    • 13.4.5 THAILAND 163
    • 13.4.6 SINGAPORE 165
    • 13.4.7 INDONESIA 167
    • 13.4.8 MALAYSIA 169
    • 13.4.9 PHILIPPINES 171
    • 13.4.10 AUSTRALIA 173
    • 13.4.11 REST OF ASIA-PACIFIC 175
  • 13.5 SOUTH AMERICA 176
    • 13.5.1 BRAZIL 183
    • 13.5.2 ARGENTINA 185
    • 13.5.3 REST OF SOUTH AMERICA 187
  • 13.6 MIDDLE EAST AND AFRICA 188
    • 13.6.1 SOUTH AFRICA 195
    • 13.6.2 SAUDI ARABIA 197
    • 13.6.3 U.A.E 199
    • 13.6.4 EGYPT 201
    • 13.6.5 ISRAEL 203
    • 13.6.6 REST OF MIDDLE EAST AND AFRICA 205

14 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 206

  • 14.1 COMPANY SHARE ANALYSIS: GLOBAL 206
  • 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 207
  • 14.3 COMPANY SHARE ANALYSIS: EUROPE 208
  • 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 209

15 SWOT ANALYSIS 210

16 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET 211

  • 16.1 F. HOFFMANN- LA ROCHE LTD 211
    • 16.1.1 COMPANY SNAPSHOT 211
    • 16.1.2 REVENUE ANALYSIS 211
    • 16.1.3 COMPANY SHARE ANALYSIS 212
    • 16.1.4 PRODUCT PORTFOLIO 212
    • 16.1.5 RECENT DEVELOPMENTS 212
  • 16.2 MERCK KGAA 213
    • 16.2.1 COMPANY SNAPSHOT 213
    • 16.2.2 REVENUE ANALYSIS 213
    • 16.2.3 COMPANY SHARE ANALYSIS 214
    • 16.2.4 PRODUCT PORTFOLIO 214
    • 16.2.5 RECENT DEVELOPMENT 214
  • 16.3 THERMO FISHER SCIENTIFIC INC. 215
    • 16.3.1 COMPANY SNAPSHOT 215
    • 16.3.2 REVENUE ANALYSIS 215
    • 16.3.3 COMPANY SHARE ANALYSIS 216
    • 16.3.4 PRODUCT PORTFOLIO 216
    • 16.3.5 RECENT DEVELOPMENT 216
  • 16.4 KONINLIJKE PHILIPS N.V. 217
    • 16.4.1 COMPANY SNAPSHOT 217
    • 16.4.2 REVENUE ANALYSIS 217
    • 16.4.3 COMPANY SHARE ANALYSIS 218
    • 16.4.4 PRODUCT PORTFOLIO 218
    • 16.4.5 RECENT DEVELOPMENT 218
  • 16.5 BIO-RAD LABORATORIES, INC. 219
    • 16.5.1 COMPANY SNAPSHOT 219
    • 16.5.2 COMPANY SNAPSHOT 219
    • 16.5.3 COMPANY SHARE ANALYSIS 220
    • 16.5.4 PRODUCT PORTFOLIO 220
    • 16.5.5 RECENT DEVELOPMENT 220
  • 16.6 ABBOTT 221
    • 16.6.1 COMPANY SNAPSHOT 221
    • 16.6.2 REVENUE ANALYSIS 221
    • 16.6.3 PRODUCT PORTFOLIO 222
    • 16.6.4 RECENT DEVELOPMENT 222
  • 16.7 AGILENT TECHNOLOGIES, INC. 223
    • 16.7.1 COMPANY SNAPSHOT 223
    • 16.7.2 REVENUE ANALYSIS 223
    • 16.7.3 PRODUCT PORTFOLIO 224
    • 16.7.4 RECENT DEVELOPMENT 224
  • 16.8 AMBU A/S 225
    • 16.8.1 COMPANY SNAPSHOT 225
    • 16.8.2 REVENUE ANALYSIS 225
    • 16.8.3 PRODUCT PORTFOLIO 226
    • 16.8.4 RECENT DEVELOPMENT 226
  • 16.9 BD 227
    • 16.9.1 COMPANY SNAPSHOT 227
    • 16.9.2 REVENUE ANALYSIS 227
    • 16.9.3 PRODUCT PORTFOLIO 228
    • 16.9.4 RECENT DEVELOPMENT 228
  • 16.10 CANON MEDICAL SYSTEMS CORPORATION 229
    • 16.10.1 COMPANY SNAPSHOT 229
    • 16.10.2 REVENUE ANALYSIS 229
    • 16.10.3 PRODUCT PORTFOLIO 230
    • 16.10.4 RECENT DEVELOPMENT 230
  • 16.11 CEPHEID 231
    • 16.11.1 COMPANY SNAPSHOT 231
    • 16.11.2 REVENUE ANALYSIS 231
    • 16.11.3 PRODUCT PORTFOLIO 232
    • 16.11.4 RECENT DEVELOPMENTS 232
  • 16.12 FUJIFILM CORPORATION 233
    • 16.12.1 COMPANY SNAPSHOT 233
    • 16.12.2 REVENUE ANALYSIS 233
    • 16.12.3 PRODUCT PORTFOLIO 234
    • 16.12.4 RECENT DEVELOPMENTS 234
  • 16.13 GENERAL ELECTRIC COMPANY 235
    • 16.13.1 COMPANY SNAPSHOT 235
    • 16.13.2 REVENUE ANALYSIS 235
    • 16.13.3 PRODUCT PORTFOLIO 236
    • 16.13.4 RECENT DEVELOPMENTS 236
  • 16.14 HOLOGIC INC. 237
    • 16.14.1 COMPANY SNAPSHOT 237
    • 16.14.2 REVENUE ANALYSIS 237
    • 16.14.3 PRODUCT PORTFOLIO 238
    • 16.14.4 RECENT DEVELOPMENT 238
  • 16.15 ILLUMINA INC 239
    • 16.15.1 COMPANY SNAPSHOT 239
    • 16.15.2 REVENUE ANALYSIS 239
    • 16.15.3 PRODUCT PORTFOLIO 240
    • 16.15.4 RECENT DEVELOPMENTS 240
  • 16.16 MINFOUND MEDICAL SYSTEMS CO., 241
    • 16.16.1 COMPANY SNAPSHOT 241
    • 16.16.2 PRODUCT PORTFOLIO 241
    • 16.16.3 RECENT DEVELOPMENTS 241
  • 16.17 NEUSOFT CORPORATION 242
    • 16.17.1 COMPANY SNAPSHOT 242
    • 16.17.2 COMPANY SNAPSHOT 242
    • 16.17.3 PRODUCT PORTFOLIO 243
    • 16.17.4 RECENT DEVELOPMENT 243
  • 16.18 QIAGEN 244
    • 16.18.1 COMPANY SNAPSHOT 244
    • 16.18.2 REVENUE ANALYSIS 244
    • 16.18.3 PRODUCT PORTFOLIO 245
    • 16.18.4 RECENT DEVELOPMENT 245
  • 16.19 SIEMENS HEALTHCARE GMBH 246
    • 16.19.1 COMPANY SNAPSHOT 246
    • 16.19.2 REVENUE ANALYSIS 246
    • 16.19.3 PRODUCT PORTFOLIO 247
    • 16.19.4 RECENT DEVELOPMENT 248
  • 16.20 TIME MEDICAL HOLDING. 249
    • 16.20.1 COMPANY SNAPSHOT 249
    • 16.20.2 PRODUCT PORTFOLIO 249
    • 16.20.3 RECENT DEVELOPMENTS 249

17 QUESTIONNAIRE 250

18 RELATED REPORTS 253

Show more

LIST OF TABLES

  • TABLE 1 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
  • TABLE 2 GLOBAL CYSTOSCOPY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 66
  • TABLE 3 GLOBAL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 67
  • TABLE 4 GLOBAL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 67
  • TABLE 5 GLOBAL BIOPSY IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
  • TABLE 6 GLOBAL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
  • TABLE 7 GLOBAL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 70
  • TABLE 8 GLOBAL OTHERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
  • TABLE 9 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 75
  • TABLE 10 GLOBAL STAGE IV IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
  • TABLE 11 GLOBAL STAGE III IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 12 GLOBAL STAGE II IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 78
  • TABLE 13 GLOBAL STAGE I IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
  • TABLE 14 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 83
  • TABLE 15 GLOBAL TRANSITIONAL CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 16 GLOBAL SQUAMOUS CELL BLADDER CANCER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
  • TABLE 17 GLOBAL OTHER CANCER TYPES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
  • TABLE 18 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 90
  • TABLE 19 GLOBAL HOSPITAL IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 20 GLOBAL DIAGNOSTIC IMAGING CENTERS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
  • TABLE 21 GLOBAL CANCER RESEARCH INSTITUTES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
  • TABLE 22 GLOBAL INDEPENDENT DIAGNOSTIC LABORATORIES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
  • TABLE 23 GLOBAL ASSOCIATED LABS IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 94
  • TABLE 24 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 98
  • TABLE 25 GLOBAL DIRECT TENDER IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
  • TABLE 26 GLOBAL RETAIL SALES IN BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
  • TABLE 27 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
  • TABLE 28 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 111
  • TABLE 29 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 30 NORTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 31 NORTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 32 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 112
  • TABLE 33 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 34 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 113
  • TABLE 35 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 113
  • TABLE 36 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 37 U.S. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 38 U.S. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 39 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 115
  • TABLE 40 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 41 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 115
  • TABLE 42 U.S. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 115
  • TABLE 43 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 44 CANADA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 45 CANADA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 46 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 117
  • TABLE 47 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 48 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 117
  • TABLE 49 CANADA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 117
  • TABLE 50 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 51 MEXICO URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 52 MEXICO IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 53 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 119
  • TABLE 54 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 55 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 119
  • TABLE 56 MEXICO BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
  • TABLE 57 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 124
  • TABLE 58 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 59 EUROPE URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 60 EUROPE IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 61 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 125
  • TABLE 62 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 63 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 126
  • TABLE 64 EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 126
  • TABLE 65 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 66 GERMANY URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 67 GERMANY IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 68 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 128
  • TABLE 69 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 70 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 128
  • TABLE 71 GERMANY BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 128
  • TABLE 72 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 73 FRANCE URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 74 FRANCE IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 75 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 130
  • TABLE 76 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 77 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
  • TABLE 78 FRANCE BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 130
  • TABLE 79 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 80 U.K. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 81 U.K. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 82 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 132
  • TABLE 83 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 132
  • TABLE 84 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 132
  • TABLE 85 U.K. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 132
  • TABLE 86 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 87 ITALY URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 88 ITALY IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 89 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 134
  • TABLE 90 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 91 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 134
  • TABLE 92 ITALY BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 134
  • TABLE 93 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 94 SPAIN URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 95 SPAIN IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 96 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 136
  • TABLE 97 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 136
  • TABLE 98 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 136
  • TABLE 99 SPAIN BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 136
  • TABLE 100 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 101 RUSSIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 102 RUSSIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 103 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 138
  • TABLE 104 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 105 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 138
  • TABLE 106 RUSSIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 138
  • TABLE 107 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 108 TURKEY URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 109 TURKEY IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 110 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 140
  • TABLE 111 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 112 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 140
  • TABLE 113 TURKEY BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 140
  • TABLE 114 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 115 NETHERLANDS URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 116 NETHERLANDS IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 117 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 142
  • TABLE 118 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 119 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 142
  • TABLE 120 NETHERLANDS BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 142
  • TABLE 121 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 122 BELGIUM URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 123 BELGIUM IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 124 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 144
  • TABLE 125 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 126 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
  • TABLE 127 BELGIUM BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 144
  • TABLE 128 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 129 SWITZERLAND URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 130 SWITZERLAND IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 131 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 146
  • TABLE 132 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 133 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 146
  • TABLE 134 SWITZERLAND BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 146
  • TABLE 135 REST OF EUROPE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 136 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 152
  • TABLE 137 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 138 ASIA-PACIFIC URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 139 ASIA-PACIFIC IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 140 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 153
  • TABLE 141 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 142 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 154
  • TABLE 143 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 154
  • TABLE 144 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 145 CHINA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 146 CHINA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 147 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 156
  • TABLE 148 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 149 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 156
  • TABLE 150 CHINA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 156
  • TABLE 151 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 152 INDIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 153 INDIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 154 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 158
  • TABLE 155 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 156 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 158
  • TABLE 157 INDIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 158
  • TABLE 158 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 159 JAPAN URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 160 JAPAN IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 161 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 160
  • TABLE 162 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 163 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 160
  • TABLE 164 JAPAN BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 160
  • TABLE 165 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 166 SOUTH KOREA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 167 SOUTH KOREA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 168 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 162
  • TABLE 169 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 170 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 162
  • TABLE 171 SOUTH KOREA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 162
  • TABLE 172 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 173 THAILAND URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 174 THAILAND IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 175 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 164
  • TABLE 176 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 177 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 164
  • TABLE 178 THAILAND BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 164
  • TABLE 179 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 180 SINGAPORE URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 181 SINGAPORE IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 182 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 166
  • TABLE 183 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 166
  • TABLE 184 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 166
  • TABLE 185 SINGAPORE BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 166
  • TABLE 186 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 187 INDONESIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 188 INDONESIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 189 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 168
  • TABLE 190 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 191 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 168
  • TABLE 192 INDONESIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 168
  • TABLE 193 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 194 MALAYSIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 195 MALAYSIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 196 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 170
  • TABLE 197 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 198 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 170
  • TABLE 199 MALAYSIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 170
  • TABLE 200 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 201 PHILIPPINES URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 202 PHILIPPINES IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 203 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 172
  • TABLE 204 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 205 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 172
  • TABLE 206 PHILIPPINES BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 172
  • TABLE 207 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 208 AUSTRALIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 209 AUSTRALIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 210 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 174
  • TABLE 211 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 212 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 174
  • TABLE 213 AUSTRALIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 174
  • TABLE 214 REST OF ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 215 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 180
  • TABLE 216 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 217 SOUTH AMERICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 218 SOUTH AMERICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 219 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 181
  • TABLE 220 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 221 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 182
  • TABLE 222 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 182
  • TABLE 223 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 224 BRAZIL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 225 BRAZIL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 226 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 184
  • TABLE 227 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 228 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 184
  • TABLE 229 BRAZIL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 184
  • TABLE 230 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 231 ARGENTINA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 232 ARGENTINA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 233 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 186
  • TABLE 234 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 235 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 186
  • TABLE 236 ARGENTINA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 186
  • TABLE 237 REST OF SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 238 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 192
  • TABLE 239 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 240 MIDDLE EAST AND AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 241 MIDDLE EAST AND AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 193
  • TABLE 242 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 193
  • TABLE 243 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 193
  • TABLE 244 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 194
  • TABLE 245 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 194
  • TABLE 246 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 247 SOUTH AFRICA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 248 SOUTH AFRICA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 249 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 196
  • TABLE 250 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 251 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 196
  • TABLE 252 SOUTH AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 196
  • TABLE 253 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 254 SAUDI ARABIA URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 255 SAUDI ARABIA IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 256 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 198
  • TABLE 257 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 258 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 198
  • TABLE 259 SAUDI ARABIA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 198
  • TABLE 260 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 199
  • TABLE 261 U.A.E. URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 199
  • TABLE 262 U.A.E. IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 199
  • TABLE 263 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 200
  • TABLE 264 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 265 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 200
  • TABLE 266 U.A.E. BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 200
  • TABLE 267 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 268 EGYPT URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 269 EGYPT IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 270 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 202
  • TABLE 271 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 202
  • TABLE 272 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 202
  • TABLE 273 EGYPT BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 202
  • TABLE 274 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 275 ISRAEL URINE LAB TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 276 ISRAEL IMAGING TEST IN BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 277 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 204
  • TABLE 278 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 204
  • TABLE 279 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 204
  • TABLE 280 ISRAEL BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 204
  • TABLE 281 REST OF MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 205

LIST OF FIGURES

  • FIGURE 1 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION 31
  • FIGURE 2 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 34
  • FIGURE 3 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 35
  • FIGURE 4 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 36
  • FIGURE 5 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 36
  • FIGURE 6 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 37
  • FIGURE 7 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 39
  • FIGURE 8 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 40
  • FIGURE 9 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 41
  • FIGURE 10 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: SEGMENTATION 44
  • FIGURE 11 RISING INCIDENCE OF BLADDER CANCER GLOBALLY IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 45
  • FIGURE 12 CYSTOSCOPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET IN 2023 & 2030 45
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 46
  • FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR BLADDER CANCER DIAGNOSTICS MARKET SERVICE PROVIDERS IN THE FORECAST PERIOD OF 2023 TO 2030 47
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BLADDER CANCER DIAGNOSTICS MARKET 55
  • FIGURE 16 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 63
  • FIGURE 17 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 64
  • FIGURE 18 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 64
  • FIGURE 19 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 65
  • FIGURE 20 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2022 73
  • FIGURE 21 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION) 74
  • FIGURE 22 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030) 74
  • FIGURE 23 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE 75
  • FIGURE 24 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 81
  • FIGURE 25 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 82
  • FIGURE 26 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 82
  • FIGURE 27 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 83
  • FIGURE 28 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2022 88
  • FIGURE 29 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 89
  • FIGURE 30 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 89
  • FIGURE 31 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 90
  • FIGURE 32 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 96
  • FIGURE 33 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 97
  • FIGURE 34 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 97
  • FIGURE 35 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 98
  • FIGURE 36 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 103
  • FIGURE 37 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY REGION (2022) 104
  • FIGURE 38 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 104
  • FIGURE 39 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 105
  • FIGURE 40 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 105
  • FIGURE 41 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 108
  • FIGURE 42 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 109
  • FIGURE 43 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 109
  • FIGURE 44 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 110
  • FIGURE 45 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 110
  • FIGURE 46 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 121
  • FIGURE 47 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 122
  • FIGURE 48 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 122
  • FIGURE 49 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 123
  • FIGURE 50 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 123
  • FIGURE 51 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 149
  • FIGURE 52 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 150
  • FIGURE 53 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 150
  • FIGURE 54 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 151
  • FIGURE 55 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 151
  • FIGURE 56 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 177
  • FIGURE 57 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 178
  • FIGURE 58 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 178
  • FIGURE 59 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 179
  • FIGURE 60 SOUTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 179
  • FIGURE 61 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 189
  • FIGURE 62 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 190
  • FIGURE 63 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 190
  • FIGURE 64 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 191
  • FIGURE 65 MIDDLE EAST AND AFRICA BLADDER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 191
  • FIGURE 66 GLOBAL BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 206
  • FIGURE 67 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 207
  • FIGURE 68 EUROPE BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 208
  • FIGURE 69 ASIA-PACIFIC BLADDER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 209
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!